Abeclib Tablet

Introduction

Abeclib Tablet 150 mg is an oral medication used primarily in the treatment of breast cancer. It is classified as a cyclin-dependent kinase (CDK) 4/6 inhibitor and is designed to target and inhibit the activity of CDK4 and CDK6, which are involved in cell cycle progression. By inhibiting these proteins, abemaciclib helps to slow down or stop the growth of cancer cells.

Uses

Abeclib Tablet 150 mg is used for the treatment of certain types of breast cancer, specifically:

Hormone Receptor-Positive Breast Cancer: For women with HR-positive, HER2-negative breast cancer, especially in cases where the disease is advanced or metastatic.
Combination Therapy: Often used in combination with other medications such as aromatase inhibitors or fulvestrant.

Brand Name	Abeclib
Type	Tablet
Weight	150 mg
Generic	Abemaciclib
Manufacturer	Eskayef Pharmaceuticals Ltd.
Available in	English বাংলা

Mechanism of Action

Abeclib Tablet 150 mg works by inhibiting the activity of CDK4 and CDK6, which are crucial for cell cycle progression. By blocking these kinases, abemaciclib prevents the transition of cells from the G1 phase to the S phase of the cell cycle, thereby slowing down the proliferation of cancer cells and potentially leading to their death.

How Long Does It Take to Work?

The therapeutic effects of abemaciclib can vary among patients. Some clinical benefits may be observed within a few weeks of starting treatment, but significant results, such as tumor shrinkage, may take several months. Regular monitoring and imaging are used to assess the effectiveness of the treatment.

Absorption

Abeclib Tablet 150 mg is well-absorbed from the gastrointestinal tract. It reaches peak plasma concentrations within approximately 1 to 3 hours after oral administration. The presence of food does not significantly affect its absorption.

Route of Elimination

Abeclib Tablet 150 mg is primarily metabolized in the liver. It is excreted mainly through feces, with a smaller amount eliminated through urine. Its metabolism involves several liver enzymes, including CYP3A4.

Dosage

Abemaciclib tablets are taken orally with or without food.

Recommended starting dose in combination with fulvestrant, tamoxifen, or an aromatase inhibitor: 150 mg twice daily.
Recommended starting dose as monotherapy: 200 mg twice daily.
Dosing interruption and/or dose reductions may be required based on individual safety and tolerability.

The standard dosage of abemaciclib is 150 mg taken orally twice daily. The dosage may vary based on the patient's condition, tolerance, and whether it is used alone or in combination with other drugs. Dose adjustments might be necessary for managing side effects.

Administration

Abeclib Tablet 150 mg is administered orally in the form of tablets. It should be taken with or without food at the same time each day. Patients should follow their healthcare provider's instructions carefully regarding dosage and administration.

Side Effects

Common side effects of abemaciclib include:

Diarrhea
Nausea
Fatigue
Decrease in appetite
Abdominal pain

Serious side effects may include neutropenia (low white blood cell count) and liver enzyme abnormalities. Patients should report any severe or persistent side effects to their healthcare provider.

Toxicity

Abeclib Tablet 150 mg has a known risk of toxicity, particularly related to hematological effects such as neutropenia. Regular blood tests are required to monitor blood cell counts. Liver function should also be monitored due to potential liver enzyme elevation.

Precautions

Precautions include:

Monitoring for signs of infection due to potential neutropenia.
Regular liver function tests to detect potential liver toxicity.
Adjusting dosage or discontinuing treatment if severe side effects occur.

Interaction

Abeclib Tablet 150 mg can interact with other medications, particularly those that affect liver enzymes such as CYP3A4. It is important to inform healthcare providers of all medications and supplements being taken.

Disease Interaction

Patients with liver impairment should use abemaciclib with caution, as it is metabolized by the liver. Dose adjustments may be required based on liver function.

Drug Interaction

Abeclib Tablet 150 mg may interact with drugs that induce or inhibit CYP3A4. Examples include:

Inhibitors: Strong CYP3A4 inhibitors like ketoconazole may increase abemaciclib levels, necessitating dose adjustments.
Inducers: CYP3A4 inducers like rifampin may decrease abemaciclib levels and effectiveness.

Food Interactions

Food does not significantly affect the absorption of abemaciclib. It can be taken with or without food. However, patients should follow specific dietary recommendations provided by their healthcare provider.

Pregnancy Use

Abeclib Tablet 150 mg is not recommended during pregnancy due to potential harm to the fetus. Women of childbearing potential should use effective contraception while on treatment and consult their healthcare provider regarding pregnancy planning.

Lactation Use

Abeclib Tablet 150 mg is not recommended for use during breastfeeding. It is unknown whether abemaciclib is excreted in breast milk, but potential risks to the infant necessitate avoiding breastfeeding during treatment.

Acute Overdose

In the event of an acute overdose, immediate medical attention is required. Symptoms of overdose may include severe side effects, such as excessive diarrhea or neutropenia. Treatment would focus on supportive care and managing symptoms.

Contraindication

Abeclib Tablet 150 mg is contraindicated in individuals with known hypersensitivity to the drug or any of its components. Patients with severe liver impairment should also avoid abemaciclib or use it with caution and under close medical supervision.

Use Direction

Patients should take abemaciclib exactly as prescribed by their healthcare provider. The medication should be taken orally, twice daily, with or without food. Adherence to the prescribed schedule and dosage is crucial for effectiveness.

Storage Conditions

Store abemaciclib at room temperature, away from moisture and heat. Keep it in its original container and out of reach of children. Ensure that the medication is used before its expiration date.

Volume of Distribution

Abeclib Tablet 150 mg has a volume of distribution of approximately 40 liters, indicating its distribution throughout the body’s tissues.

Half Life

The terminal half-life of abemaciclib is approximately 16 to 18 hours. This allows for twice-daily dosing to maintain therapeutic levels.

Clearance

Abeclib Tablet 150 mg is cleared primarily through metabolism in the liver. The clearance rate may be affected by liver function, necessitating dose adjustments in patients with hepatic impairment.

See in details version Abeclib Tablet 150 mg also Abeclib Tablet 150 mg in bangla